{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:41:19Z","timestamp":1761864079167,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>Recent years have seen an increase in use of mepolizumab and other biological therapies for the treatment of severe eosinophilic asthma. A few cases of paradoxical responses to mepolizumab therapy have now been reported and are hypothesised as being a response to immune complex formation. We present a case of mepolizumab-induced alopecia in a patient with paradoxical adverse response to mepolizumab given for severe eosinophilic asthma. We postulate this could be secondary to autoimmune mechanisms and that it could help herald poor response to treatment, thereby facilitating early identification of patients having paradoxical responses.<\/jats:p>","DOI":"10.1136\/bcr-2019-233161","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T04:25:13Z","timestamp":1582259113000},"page":"e233161","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma"],"prefix":"10.1136","volume":"13","author":[{"given":"Rodanthe","family":"Nixon","sequence":"first","affiliation":[{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Despiney","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2025082703491915000_13.2.e233161.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2025082703491915000_13.2.e233161.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84144"},{"key":"2025082703491915000_13.2.e233161.3","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082703491915000_13.2.e233161.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812"},{"key":"2025082703491915000_13.2.e233161.5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13223-016-0174-5","article-title":"Airway autoimmune responses in severe eosinophilic asthma following low-dose mepolizumab therapy","volume":"13","author":"Mukherjee","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2025082703491915000_13.2.e233161.6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4168\/aair.2018.10.5.428","article-title":"Autoimmune responses in severe asthma","volume":"10","author":"Mukherjee","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"2025082703491915000_13.2.e233161.7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-Adjusted intravenous Reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025082703491915000_13.2.e233161.8","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-Term safety and efficacy of Reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082703491915000_13.2.e233161.9","unstructured":"National Institute for Health and Care Excellence . Mepolizumab for treating severe refractory eosinophilic asthma. London: NICE, 2017. https:\/\/www.nice.org.uk\/guidance\/ta431"},{"key":"2025082703491915000_13.2.e233161.10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/PGS.15.54","article-title":"Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity","volume":"16","author":"Chan","year":"2015","journal-title":"Pharmacogenomics"},{"key":"2025082703491915000_13.2.e233161.11","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-233161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:49:27Z","timestamp":1756291767000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-233161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,20]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/bcr-2019-233161"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-233161","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}